Document is current

Article History

Received: 4 November 2025

Accepted: 17 February 2026

First Online: 28 March 2026

Declarations

:

: All patients provided informed consent for case discussion and data entry at the ENKID multidisciplinary team meetings. The Cambridge University Hospitals NHS Foundation Trust Institutional Review Board determined that ethical approval was not required for this service evaluation (Project ID 7581), in accordance with UK NHS Research Ethics Committee guidelines ( ). This work comprises retrospective data, and all treatment decisions were made before our evaluation. No patient outcome data and only limited demographic data are reported. This study was conducted in accordance with the principles of the Declaration of Helsinki.

: Not applicable.

: Outside the scope of this work, L.F. has received honoraria from CSL Vifor and Addenbrooke’s Charitable Trust. K.W.L had advisory board and consulting fees: Boehringer Ingelheim, CSL Vifor; honoraria for presentations: Astra Zeneca; support for attending meetings: Novartis. L.C.W. is an investigator in clinical trials sponsored by Chemocentryx, Rigel, Novartis and GSK. R.M.S has received research grants from Union Therapeutics, GlaxoSmithKline, LifeArc, Kidney Research UK and Addenbrooke’s Charitable Trust. F.C.H has received contributions towards trials from Alexion Pharmaceuticals and Eli Lilly and Company and UK Research and Innovation; and towards research infrastructure from the UK National Institute for Health and Care Research and reports payment for weekend shifts for Clinical Investigators from Addenbrooke’s Charitable Trust. D.R.W.J. has received research or educational grants from Chemocentryx, GSK, InflaRx, and Sanofi, and received consulting fees from Celgene, Chemocentryx, GSK, InflaRX and Insmed. R.B.J. has research grants from CSL Vifor and Roche, Honorarium from Roche, Consultancy from CSL Vifor. All other authors have no competing interests to declare.